Form 8-K - Current report:
SEC Accession No. 0000950170-25-009227
Filing Date
2025-01-27
Accepted
2025-01-27 16:30:09
Documents
14
Period of Report
2025-01-27
Items
Item 5.07: Submission of Matters to a Vote of Security Holders
Item 7.01: Regulation FD Disclosure
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K lctx-20250127.htm   iXBRL 8-K 63438
2 EX-4.1 lctx-ex4_1.htm EX-4.1 147537
3 EX-99.1 lctx-ex99_1.htm EX-99.1 21354
4 GRAPHIC img176613450_0.jpg GRAPHIC 40918
  Complete submission text file 0000950170-25-009227.txt   401566

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT lctx-20250127.xsd EX-101.SCH 23883
16 EXTRACTED XBRL INSTANCE DOCUMENT lctx-20250127_htm.xml XML 4516
Mailing Address 2173 SALK AVENUE SUITE 200 CARLSBAD CA 92008
Business Address 2173 SALK AVENUE SUITE 200 CARLSBAD CA 92008 5105213390
Lineage Cell Therapeutics, Inc. (Filer) CIK: 0000876343 (see all company filings)

EIN.: 943127919 | State of Incorp.: CA | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-12830 | Film No.: 25559432
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)